Literature DB >> 6309441

Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.

M A Epstein, A J Morgan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6309441      PMCID： PMC1535689     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  108 in total

1.  Appearance of Epstein-Barr virus-associated antigens in infected Raji cells.

Authors:  L Gergely; G Klein; I Ernberg
Journal:  Virology       Date:  1971-07       Impact factor: 3.616

Review 2.  Etiology of Burkitt's lymphoma--an alternative hypothesis to a vectored virus.

Authors:  D P Burkitt
Journal:  J Natl Cancer Inst       Date:  1969-01       Impact factor: 13.506

3.  Immunization against Marek's disease using a live attenuated virus.

Authors:  A E Churchill; L N Payne; R C Chubb
Journal:  Nature       Date:  1969-02-22       Impact factor: 49.962

Review 4.  Persistent immunologic stimulation as a factor in oncogenesis, with special reference to Burkitt's tumor.

Authors:  G T O'Connor
Journal:  Am J Med       Date:  1970-03       Impact factor: 4.965

5.  Clonal origin for individual Burkitt tumours.

Authors:  P J Fialkow; G Klein; S M Gartler; P Clifford
Journal:  Lancet       Date:  1970-02-21       Impact factor: 79.321

6.  Protection against Marek's disease by vaccination with a herpesvirus of turkeys.

Authors:  W Okazaki; H G Purchase; B R Burmester
Journal:  Avian Dis       Date:  1970-05       Impact factor: 1.577

Review 7.  A review on the epidemiology of nasopharyngeal carcinoma.

Authors:  P Clifford
Journal:  Int J Cancer       Date:  1970-05-15       Impact factor: 7.396

8.  Histopathological definition of Burkitt's tumour.

Authors: 
Journal:  Bull World Health Organ       Date:  1969-04       Impact factor: 9.408

9.  The relation between the Epstein-Barr virus and infectious mononucleosis, Burkitt's lymphoma and cancer of the postnasal space.

Authors:  W Henle; G Henle
Journal:  East Afr Med J       Date:  1969-07

10.  Burkitt's lymphoma outside the known endemic areas of Africa and New Guinea.

Authors:  D Burkitt
Journal:  Int J Cancer       Date:  1967-11-15       Impact factor: 7.396
View more
  6 in total

1.  Increased frequency of antibodies to ubiquitous viruses in essential mixed cryoglobulinaemia.

Authors:  G Fiorini; P Bernasconi; R A Sinico; R Chianese; F Pozzi; G D'Amico
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

2.  Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.

Authors:  M A Epstein; B J Randle; S Finerty; J K Kirkwood
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

3.  S-100 protein positive cells in nasopharyngeal carcinoma (NPC): absence of prognostic significance. A clinicopathological and immunohistochemical study of 40 cases.

Authors:  F J Vera-Sempere; C Micheau; A Llombart-Bosch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Detection of S-100 labelled cells in nasopharyngeal carcinoma.

Authors:  L Lauriola; F Michetti; S Sentinelli; D Cocchia
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

5.  Plasmodium falciparum products enhance human lymphocyte transformation by Epstein-Barr virus.

Authors:  P K Kataaha; C A Facer; E J Holborow
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

6.  EBV-positive human sera contain antibodies against the EBV BMRF-2 protein.

Authors:  Jianqiao Xiao; Joel M Palefsky; Rossana Herrera; Carl Sunshine; Sharof M Tugizov
Journal:  Virology       Date:  2009-08-20       Impact factor: 3.616
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.